RBC Capital analyst Luca Issi initiated coverage with a Hold rating on Adverum Biotechnologies (ADVM – Research Report) yesterday and set a price target of $2.00. The company’s shares closed yesterday at $1.77.
According to TipRanks, Issi is an analyst with an average return of -20.5% and a 23.66% success rate. Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ionis Pharmaceuticals, and uniQure.
Currently, the analyst consensus on Adverum Biotechnologies is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.97 and a one-year low of $0.68. Currently, Adverum Biotechnologies has an average volume of 2.13M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adverum Biotechnologies (ADVM) Company Description:
Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich’s ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr. and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
Read More on ADVM:
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
- Adverum Biotechnologies files to sell 106.48M shares of common stock for holders
- ADVM Upcoming Earnings Report: What to Expect?
- Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
- Adverum’s Ixoberogene Soroparvovec Shows Promise in LUNA Trial